Skip to main content

Table 3 Immunohistochemical comparison of the different markers used in the two series

From: Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin

   IBC Non-IBC p value
   n (%) n (%)  
ER Negative 42 (53.85%) 99 (26.26%) <0.001
  Positive 36 (46.15%) 278 (73.74%)  
PR Negative 37 (52.86%) 132 (35.39%) <0.01
  Positive 33 (47.14%) 241 (64.61%)  
ERBB2 0–1 48 (66.67%) 301 (85.51%) <0.001
  2–3 24 (33.33%) 51 (14.49%)  
EGFR Negative 57 (77.03%) 240 (75.24%) >0.05
  Positive 17 (22.97%) 79 (24.76%)  
CK5/6 Negative 47 (61.04%) 191 (67.25%) >0.05
  Positive 30 (38.96%) 93 (32.75%)  
CK14 Negative 38 (80.85%) 295 (94.55%) <0.01
  Positive 9 (19.15%) 17 (5.45%)  
P-cadherin Negative 13 (24.07%) 169 (51.84%) <0.001
  Positive 41 (75.93%) 157 (48.16%)  
P53 Negative 43 (58.11%) 253 (69.7%) >0.05
  Positive 31 (41.89%) 110 (30.3%)  
MUC1 Negative 5 (6.67%) 42 (12.84%) >0.05
  Positive 70 (93.33%) 285 (87.16%)  
CAV1 Negative 22 (31.43%) 105 (31.16%) >0.05
  Positive 48 (68.57%) 232 (68.84%)  
CAV2 Negative 45 (90%) 212 (89.83%) >0.05
  Positive 5 (10%) 35 (10.17%)  
MIB1 ≤20 43 (58.9%) 295 (87.02%) <0.001
  >20 30 (41.1%) 44 (12.98%)